Indegene hosts Digital Summit 2026 to drive AI outcomes in life sciences
- Indegene Limited hosted the eighth Indegene Digital Summit in Philadelphia on September 22, 2026
- Over 200 life sciences leaders attended to discuss operationalizing AI for enterprise outcomes
- The VITAL Awards recognized leaders in Organizational Impact, Market Impact, and Transformational Leadership
- Key themes included rewiring operating models to support precision medicines and AI-driven decision-making
*this image is generated using AI for illustrative purposes only.
Indegene Limited convened senior life sciences leaders for the eighth edition of the Indegene Digital Summit, focusing on translating artificial intelligence investments into measurable business impact. The event, held September 22 at the National Constitution Center in Philadelphia, gathered over 200 global executives to discuss operationalizing AI within regulated environments.
The summit’s theme, "From Promise to Performance: Operationalizing AI for Enterprise Outcomes," addressed the industry challenge of applying new technologies to legacy operating models. Discussions centered on why existing frameworks are insufficient for modern precision medicines and what changes are required in work, data, decisions, content, governance, talent, and partnerships. Manish Gupta, Chairman and CEO of Indegene, emphasized that specialized therapies cannot be supported by mass promotion models, urging a rewire of enterprise systems around AI to enhance speed and responsiveness.
Key discussions and speaker insights
Sessions explored customer engagement in 2028, AI-enabled launch models, and the connection between AI and profit-and-loss impact. Speakers included David Shulkin, Ninth Secretary of the U.S. Department of Veterans Affairs; Amol Punjabi, Chief Product Officer, Open Evidence; Agam Upadhyay, SVP and Chief Digital & Information Officer, Vertex Pharmaceuticals; and Tarun Mathur, Chief Technology Officer, Indegene. Other notable participants represented Pfizer, Sanofi, Jazz Pharmaceuticals, J&J Innovative Medicine, BioMarin Pharmaceutical Inc., Cingulate Therapeutics, and Sun Pharma.
Key themes emerging from the dialogues included:
- A recognition that operationalizing AI requires a next-generation, life-sciences native operating model powered by domain understanding.
- The role of AI in connecting data, intelligence, and evidence to enable strategic decisions.
- The potential for AI to drive successful product launches, deliver personalized customer experiences, and accelerate drug discovery and clinical research.
VITAL Awards honor industry leaders
The summit hosted the second edition of the VITAL Awards, recognizing leaders delivering measurable industry impact across two jury-evaluated categories: Organizational Impact and Market Impact. Special awards were also given for Transformational Leadership. The jury comprised experts from life sciences, healthcare, research, media, and industry leadership, including Jill DeSimone, former U.S. Head of Oncology, Merck; Michelle Keefe, former CEO, Syneos Health; and Aida Habtezion, former Chief Medical Officer, Pfizer.
VITAL Awards 2026 honorees
| Category | Honorees |
|---|---|
| Transformational Leadership | Brian Cantwell, VP, Head of AI, US Pharma, Bayer; Agam Upadhyay, SVP, Chief Digital and Information Officer, Vertex |
| Organizational Impact | Amanda Marvel, Senior Marketing Director, Gilead Sciences; Saket Malhotra, Global Head of Commercial Digital, BioMarin |
| Market Impact | Lauren Jones, Head of Digital Marketing, Incyte; Nicholas Lucente, US Product Lead, Secondary Stroke Prevention, Bayer |
Manish Gupta stated that the honorees demonstrate that meaningful progress is driven by leaders combining bold thinking with determination to turn ideas into measurable impact. The Indegene Digital Summit serves as the company’s flagship thought leadership platform, facilitating dialogue among senior executives, regulators, and digital innovators under the #FutureReadyHealthcare initiative.
Historical Stock Returns for Indegene
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.06% | +4.71% | +5.39% | +35.80% | +3.60% | +4.82% |
How will regulatory bodies adapt compliance frameworks to accommodate AI-driven decision-making in precision medicine launches?
What specific ROI metrics will life sciences firms use to validate the transition from mass promotion to AI-personalized engagement models?
To what extent will the adoption of 'life-sciences native' operating models disrupt traditional vendor partnerships in the pharmaceutical supply chain?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
